BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother 2017;13:2138-49. [PMID: 28605249 DOI: 10.1080/21645515.2017.1337614] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
Number Citing Articles
1 Sá JM, Piloto JV, Cilli EM, Tasic L, Fossey MA, Almeida FCL, Souza FP, Caruso ÍP. Hesperetin targets the hydrophobic pocket of the nucleoprotein/phosphoprotein binding site of human respiratory syncytial virus. J Biomol Struct Dyn 2020;:1-13. [PMID: 33076779 DOI: 10.1080/07391102.2020.1835717] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Takeuchi M, Kawakami K. Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series. Hum Vaccin Immunother 2021;17:1235-8. [PMID: 32961094 DOI: 10.1080/21645515.2020.1809265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Filardo S, Di Pietro M, Mastromarino P, Sessa R. Therapeutic potential of resveratrol against emerging respiratory viral infections. Pharmacol Ther 2020;214:107613. [PMID: 32562826 DOI: 10.1016/j.pharmthera.2020.107613] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
4 Ren J, Wu W, Zhang K, Choi EJ, Wang P, Ivanciuc T, Peniche A, Qian Y, Garofalo RP, Zhou J, Bao X. Exchange Protein Directly Activated by cAMP 2 Enhances Respiratory Syncytial Virus-Induced Pulmonary Disease in Mice. Front Immunol 2021;12:757758. [PMID: 34733289 DOI: 10.3389/fimmu.2021.757758] [Reference Citation Analysis]
5 Dibo M, Battocchio EC, dos Santos Souza LM, da Silva MDV, Banin-hirata BK, Sapla MM, Marinello P, Rocha SP, Faccin-galhardi LC. Antibody Therapy for the Control of Viral Diseases: An Update. CPB 2019;20:1108-21. [DOI: 10.2174/1389201020666190809112704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
6 Krilov LR, Anderson EJ. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics. J Perinatol 2020;40:1135-44. [PMID: 32499597 DOI: 10.1038/s41372-020-0689-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zhang C, Wang Y, Zhu Y, Liu C, Gu C, Xu S, Wang Y, Zhou Y, Wang Y, Han W, Hong X, Yang Y, Zhang X, Wang T, Xu C, Hong Q, Wang S, Zhao Q, Qiao W, Zang J, Kong L, Wang F, Wang H, Qu D, Lavillette D, Tang H, Deng Q, Xie Y, Cong Y, Huang Z. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat Commun 2021;12:264. [PMID: 33431876 DOI: 10.1038/s41467-020-20465-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
8 Xu J, Wu W, Chen H, Xue Y, Bao X, Zhou J. Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses. Bioorg Med Chem 2021;39:116157. [PMID: 33895704 DOI: 10.1016/j.bmc.2021.116157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Xun G, Song X, Hu J, Zhang H, Liu L, Zhang Z, Gong R. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein. J Virol 2021;95:e0048521. [PMID: 34160257 DOI: 10.1128/JVI.00485-21] [Reference Citation Analysis]
10 Zou X, Wu J, Gu J, Shen L, Mao L. Application of Aptamers in Virus Detection and Antiviral Therapy. Front Microbiol 2019;10:1462. [PMID: 31333603 DOI: 10.3389/fmicb.2019.01462] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 22.3] [Reference Citation Analysis]
11 Quinn LA, Shields MD, Groves HE. Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a protocol for a systematic review. Syst Rev 2019;8:333. [PMID: 31856889 DOI: 10.1186/s13643-019-1251-x] [Reference Citation Analysis]
12 Kamori A, Morooka Y, Yamamura K, Chong PF, Kuga N, Takahata Y, Sagawa K, Furuno K. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study. Medicine (Baltimore) 2021;100:e27952. [PMID: 34964779 DOI: 10.1097/MD.0000000000027952] [Reference Citation Analysis]
13 Viguria N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Hum Vaccin Immunother 2021;17:1867-72. [PMID: 33502928 DOI: 10.1080/21645515.2020.1843336] [Reference Citation Analysis]
14 Choi EJ, Ren Y, Chen Y, Liu S, Wu W, Ren J, Wang P, Garofalo RP, Zhou J, Bao X. Exchange Proteins Directly Activated by cAMP and Their Roles in Respiratory Syncytial Virus Infection. J Virol 2018;92:e01200-18. [PMID: 30185593 DOI: 10.1128/JVI.01200-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
15 Zurawski DV, McLendon MK. Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens. Antibiotics (Basel) 2020;9:E155. [PMID: 32244733 DOI: 10.3390/antibiotics9040155] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
16 Gomi R, Sharma A, Wu W, Worgall S. Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV. Vaccines (Basel) 2018;7:E3. [PMID: 30597977 DOI: 10.3390/vaccines7010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Rando HM, Wellhausen N, Ghosh S, Lee AJ, Dattoli AA, Hu F, Byrd JB, Rafizadeh DN, Lordan R, Qi Y, Sun Y, Brueffer C, Field JM, Ben Guebila M, Jadavji NM, Skelly AN, Ramsundar B, Wang J, Goel RR, Park Y, Boca SM, Gitter A, Greene CS; COVID-19 Review Consortium Vikas Bansal, John P. Barton, Simina M. Boca, Joel D. Boerckel, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Daniel S. Himmelstein, Fengling Hu, Nafisa M. Jadavji, Jeremy P. Kamil, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D’Agostino McGowan, Amruta Naik, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Vincent Rubinetti, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Yusha Sun, Gregory L. Szeto, Ryan Velazquez, Jinhui Wang, Nils Wellhausen. Identification and Development of Therapeutics for COVID-19. mSystems 2021;:e0023321. [PMID: 34726496 DOI: 10.1128/mSystems.00233-21] [Reference Citation Analysis]
18 Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J 2020;29:32-61. [PMID: 32546899 DOI: 10.1007/s15007-020-2550-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
19 Nagasawa K, Ishiwada N. Disease burden of respiratory syncytial virus infection in the pediatric population in Japan. J Infect Chemother 2021:S1341-321X(21)00318-4. [PMID: 34952776 DOI: 10.1016/j.jiac.2021.11.007] [Reference Citation Analysis]
20 Daurach M, Michel-behnke I. Respiratory Syncytial Virus Infections among Children with Congenital Heart Disease. In: Resch B, editor. The Burden of Respiratory Syncytial Virus Infection in the Young. IntechOpen; 2019. [DOI: 10.5772/intechopen.85552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Najioullah F, Bancons P, Césaire R, Fléchelles O. Seasonality and coinfection of bronchiolitis: epidemiological specificity and consequences in terms of prophylaxis in tropical climate. Trop Med Int Health 2020;25:1291-7. [PMID: 32628347 DOI: 10.1111/tmi.13462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Mitchell I, Wong SK, Paes B, Ruff M, Bjornson C, Li A, Lanctôt KL; CARESS investigators. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016). Eur J Clin Microbiol Infect Dis 2018;37:1345-52. [PMID: 29728782 DOI: 10.1007/s10096-018-3256-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hu M, Bogoyevitch MA, Jans DA. Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies. Physiol Rev 2020;100:1527-94. [PMID: 32216549 DOI: 10.1152/physrev.00030.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Glatman-Freedman A, Kaufman Z, Applbaum Y, Dichtiar R, Steiman A, Gordon ES, Keinan-Boker L, Shohat T, Haklai Z. Respiratory Syncytial Virus hospitalization burden: a nation-wide population-based analysis, 2000-2017. J Infect 2020;81:297-303. [PMID: 32504738 DOI: 10.1016/j.jinf.2020.05.078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Vázquez Y, González L, Noguera L, González PA, Riedel CA, Bertrand P, Bueno SM. Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update. Front Immunol 2019;10:1154. [PMID: 31214165 DOI: 10.3389/fimmu.2019.01154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
26 Deal CE, Carfi A, Plante OJ. Advancements in mRNA Encoded Antibodies for Passive Immunotherapy. Vaccines (Basel) 2021;9:108. [PMID: 33572679 DOI: 10.3390/vaccines9020108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Abu-Raya B, Maertens K. Protection of the Newborn Through Vaccination in Pregnancy. Neoreviews 2021;22:e25-39. [PMID: 33386312 DOI: 10.1542/neo.22-1-e25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Livingstone MC, Bitzer AA, Giri A, Luo K, Sankhala RS, Choe M, Zou X, Dennison SM, Li Y, Washington W, Ngauy V, Tomaras GD, Joyce MG, Batchelor AH, Dutta S. In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP). Sci Rep 2021;11:5318. [PMID: 33674699 DOI: 10.1038/s41598-021-84622-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Hou X, Zhang X, Bi J, Zhu A, He L. Indole-3-carboxaldehyde regulates RSV-induced inflammatory response in RAW264.7 cells by moderate inhibition of the TLR7 signaling pathway. J Nat Med 2021;75:602-11. [PMID: 33755912 DOI: 10.1007/s11418-021-01506-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Mesa-Frias M, Rossi C, Emond B, Bookhart B, Anderson D, Drummond S, Wang J, Lefebvre P, Lamerato LE, Lafeuille MH. Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases. J Manag Care Spec Pharm 2022;28:753-65. [PMID: 35503888 DOI: 10.18553/jmcp.2022.21459] [Reference Citation Analysis]
31 Sierra CM, Park A, Eum E, Garcia G, Lopez M, Daniel SN, Bahjri K, Parbuoni KA. Adherence to the 2014 American Academy of Pediatrics palivizumab prophylaxis recommendations. Pediatr Pulmonol 2021;56:1121-6. [PMID: 33314771 DOI: 10.1002/ppul.25225] [Reference Citation Analysis]
32 Thakar J, Qian Y, Benoodt L, Roumanes D, Qiu X, Laniewski N, Chu C, Slaunwhite C, Wang L, Mandava A, Chang I, Falsey AR, Caserta MT, Mariani TJ, Scheuermann RH, Walsh EE, Topham DJ. Unbiased analysis of peripheral blood mononuclear cells reveals CD4 T cell response to RSV matrix protein. Vaccine X 2020;5:100065. [PMID: 32529184 DOI: 10.1016/j.jvacx.2020.100065] [Reference Citation Analysis]
33 Kumar R, Qureshi H, Deshpande S, Bhattacharya J. Broadly neutralizing antibodies in HIV-1 treatment and prevention. Ther Adv Vaccines Immunother 2018;6:61-8. [PMID: 30345419 DOI: 10.1177/2515135518800689] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
34 Atherton LJ, Jorquera PA, Bakre AA, Tripp RA. Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types. Front Immunol 2019;10:2323. [PMID: 31649663 DOI: 10.3389/fimmu.2019.02323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Zhu G, Xu D, Zhang Y, Wang T, Zhang L, Gu W, Shen M. Epidemiological characteristics of four common respiratory viral infections in children. Virol J 2021;18:10. [PMID: 33407659 DOI: 10.1186/s12985-020-01475-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Domachowske JB, Anderson EJ, Goldstein M. The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. Infect Dis Ther 2021;10:47-60. [PMID: 33656652 DOI: 10.1007/s40121-020-00383-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
37 Sanders SL, Agwan S, Hassan M, van Driel ML, Del Mar CB. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Cochrane Database Syst Rev 2019;8:CD009417. [PMID: 31446622 DOI: 10.1002/14651858.CD009417.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Hu M, Bogoyevitch MA, Jans DA. Subversion of Host Cell Mitochondria by RSV to Favor Virus Production is Dependent on Inhibition of Mitochondrial Complex I and ROS Generation. Cells 2019;8:E1417. [PMID: 31717900 DOI: 10.3390/cells8111417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
39 Pischedda S, Rivero-Calle I, Gómez-Carballa A, Cebey-López M, Barral-Arca R, Gómez-Rial J, Pardo-Seco J, Curras-Tuala MJ, Viz-Lasheras S, Bello X, Crujeiras AB, Diaz-Lagares A, González-López MT, Martinón-Torres F, Salas A; GENDRES consortium. Role and Diagnostic Performance of Host Epigenome in Respiratory Morbidity after RSV Infection: The EPIRESVi Study. Front Immunol 2022;13:875691. [PMID: 35619695 DOI: 10.3389/fimmu.2022.875691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kleinert RDV, Montoya-Diaz E, Khera T, Welsch K, Tegtmeyer B, Hoehl S, Ciesek S, Brown RJP. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. Viruses 2019;11:E960. [PMID: 31627415 DOI: 10.3390/v11100960] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Bergeron HC, Tripp RA. Immunopathology of RSV: An Updated Review. Viruses 2021;13:2478. [PMID: 34960746 DOI: 10.3390/v13122478] [Reference Citation Analysis]
42 Baraldi E, Bonadies L, Manzoni P. Evidence on the Link between Respiratory Syncytial Virus Infection in Early Life and Chronic Obstructive Lung Diseases. Am J Perinatol 2020;37:S26-30. [PMID: 32772357 DOI: 10.1055/s-0040-1714345] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
43 Abu-Raya B, Maertens K, Edwards KM, Omer SB, Englund JA, Flanagan KL, Snape MD, Amirthalingam G, Leuridan E, Damme PV, Papaevangelou V, Launay O, Dagan R, Campins M, Cavaliere AF, Frusca T, Guidi S, O'Ryan M, Heininger U, Tan T, Alsuwaidi AR, Safadi MA, Vilca LM, Wanlapakorn N, Madhi SA, Giles ML, Prymula R, Ladhani S, Martinón-Torres F, Tan L, Michelin L, Scambia G, Principi N, Esposito S. Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. Front Immunol 2020;11:1282. [PMID: 32670282 DOI: 10.3389/fimmu.2020.01282] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
44 Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Eur J Clin Microbiol Infect Dis 2018;37:1113-8. [PMID: 29557081 DOI: 10.1007/s10096-018-3225-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
45 Thakur N, Conceicao C, Isaacs A, Human S, Modhiran N, McLean RK, Pedrera M, Tan TK, Rijal P, Townsend A, Taylor G, Young PR, Watterson D, Chappell KJ, Graham SP, Bailey D. Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion. J Gen Virol 2021;102. [PMID: 33054904 DOI: 10.1099/jgv.0.001506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Mathew S, Taleb S, Eid AH, Althani AA, Yassine HM. In silico virtual screening of lead compounds for major antigenic sites in respiratory syncytial virus fusion protein. Emergent Mater 2021;:1-11. [PMID: 33969268 DOI: 10.1007/s42247-021-00213-6] [Reference Citation Analysis]
47 Quan FS, Basak S, Chu KB, Kim SS, Kang SM. Progress in the development of virus-like particle vaccines against respiratory viruses. Expert Rev Vaccines 2020;19:11-24. [PMID: 31903811 DOI: 10.1080/14760584.2020.1711053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
48 Chau-Etchepare F, Hoerger JL, Kuhn BT, Zeki AA, Haczku A, Louie S, Kenyon NJ, Davis CE, Schivo M. Viruses and non-allergen environmental triggers in asthma. J Investig Med 2019;67:1029-41. [PMID: 31352362 DOI: 10.1136/jim-2019-001000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
49 Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int 2020;29:97-125. [PMID: 32421085 DOI: 10.1007/s40629-020-00126-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
50 Casadevall A, Pirofski LA, Joyner MJ. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. mBio 2021;12:e03372-20. [PMID: 33653885 DOI: 10.1128/mBio.03372-20] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
51 Bergeron HC, Tripp RA. Emerging small and large molecule therapeutics for respiratory syncytial virus. Expert Opin Investig Drugs 2020;29:285-94. [PMID: 32096420 DOI: 10.1080/13543784.2020.1735349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Sah BNP, Lueangsakulthai J, Kim BJ, Hauser BR, Woo Y, Olyaei A, Aloia M, O'Connor A, Scottoline B, Pastey MK, Dallas DC. Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation. Front Nutr 2020;7:130. [PMID: 32923453 DOI: 10.3389/fnut.2020.00130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
53 Hamza A, Samad A, Imam MA, Faizan MI, Ahmed A, Almajhdi FN, Hussain T, Islam A, Parveen S. Structural Characterization of Ectodomain G Protein of Respiratory Syncytial Virus and Its Interaction with Heparan Sulfate: Multi-Spectroscopic and In Silico Studies Elucidating Host-Pathogen Interactions. Molecules 2021;26:7398. [PMID: 34885979 DOI: 10.3390/molecules26237398] [Reference Citation Analysis]
54 Rocca A, Biagi C, Scarpini S, Dondi A, Vandini S, Pierantoni L, Lanari M. Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now? Int J Mol Sci 2021;22:3703. [PMID: 33918185 DOI: 10.3390/ijms22073703] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
55 Nuñez Castrejon AM, O'Rourke SM, Kauvar LM, DuBois RM. Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens. J Virol 2022;:e0220121. [PMID: 35266806 DOI: 10.1128/jvi.02201-21] [Reference Citation Analysis]
56 Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G, Lanari M. Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines. Vaccines (Basel) 2020;8:E672. [PMID: 33187337 DOI: 10.3390/vaccines8040672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
57 Hu M, Schulze KE, Ghildyal R, Henstridge DC, Kolanowski JL, New EJ, Hong Y, Hsu AC, Hansbro PM, Wark PA, Bogoyevitch MA, Jans DA. Respiratory syncytial virus co-opts host mitochondrial function to favour infectious virus production. Elife 2019;8:e42448. [PMID: 31246170 DOI: 10.7554/eLife.42448] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
58 Krilov LR, Domachowske JB, Anderson EJ. RSV Disease: Current Management and the Future of Treatment and Prevention. Infect Dis Ther 2021;10:1-3. [PMID: 33660240 DOI: 10.1007/s40121-020-00386-3] [Reference Citation Analysis]
59 Bergeron HC, Murray J, Nuñez Castrejon AM, DuBois RM, Tripp RA. Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies. Viruses 2021;13:352. [PMID: 33672319 DOI: 10.3390/v13020352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Vakrilova L, Nikolova SH, Slavov S, Radulova P, Slancheva B. An outbreak of RSV infections in a neonatology clinic during the RSV-season. BMC Pediatr 2021;21:567. [PMID: 34895173 DOI: 10.1186/s12887-021-03053-9] [Reference Citation Analysis]
61 Frey SJ, Varner C, Arsiwala A, Currier MG, Moore ML, Kane RS. The Design of Vaccines Based on the Shielding of Antigenic Site Ø of a Respiratory Syncytial Virus Fusion Protein Immunogen. Adv Healthc Mater 2021;10:e2000714. [PMID: 32755047 DOI: 10.1002/adhm.202000714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Schiller ZA, Rudolph MJ, Toomey JR, Ejemel M, LaRochelle A, Davis SA, Lambert HS, Kern A, Tardo AC, Souders CA, Peterson E, Cannon RD, Ganesa C, Fazio F, Mantis NJ, Cavacini LA, Sullivan-Bolyai J, Hu LT, Embers ME, Klempner MS, Wang Y. Blocking Borrelia burgdorferi transmission from infected ticks to nonhuman primates with a human monoclonal antibody. J Clin Invest 2021;131:144843. [PMID: 33914704 DOI: 10.1172/JCI144843] [Reference Citation Analysis]
63 Quinn LA, Shields MD, Sinha I, Groves HE. Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review. Syst Rev 2020;9:269. [PMID: 33239107 DOI: 10.1186/s13643-020-01527-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Fainardi V, Nicoletti L, Conte C, Massa S, Torelli L, Scarpa AA, Casolari E, Esposito SMR, Pisi G. Congenital malformations potentially affecting respiratory function: multidisciplinary approach and follow-up. Acta Biomed 2020;92:e2021069. [PMID: 33682830 DOI: 10.23750/abm.v92i1.10591] [Reference Citation Analysis]
65 Choi EJ, Wu W, Cong X, Zhang K, Luo J, Ye S, Wang P, Suresh A, Ullah UM, Zhou J, Bao X. Broad Impact of Exchange Protein Directly Activated by cAMP 2 (EPAC2) on Respiratory Viral Infections. Viruses 2021;13:1179. [PMID: 34205489 DOI: 10.3390/v13061179] [Reference Citation Analysis]
66 Mitchell I, Li A, Bjornson CL, Lanctot KL, Paes BA; CARESS investigators. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada. Am J Perinatol 2021. [PMID: 33657636 DOI: 10.1055/s-0041-1725146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]